Platform Expansion Leverage InSphero's integrated 3D spheroid platform across liver safety, liver disease, islet biology, and oncology/immunology to offer a comprehensive safety and efficacy screening package; capitalize on the GI toxicity platform launch to broaden the disease scope and cross-sell with existing DILI services; opportunities to package features and offer multi-portfolio deals to pharma and biotech clients.

Acquisition Momentum Backed by strategic acquisitions in high-content imaging and organoid tech, InSphero can position as a one-stop solution for phenotypic screening and organ-specific models; target imaging-focused CROs and pharma teams seeking end-to-end data from organoids to analytics; tailor proposals that emphasize integrated workflows.

Partnership Ecosystem Existing and potential partnerships (PharmaNest, Genome Biologics, Doppl, Sun Bioscience) signal a channel-driven growth model; pursue co-development agreements, exclusive licensing, and joint go-to-market with digital pathology, imaging analytics, and organoid tech to expand reach.

Global Growth With a European base and active US partnerships and acquisitions, InSphero is well-positioned to support global drug safety programs; sales motions can target global pharma and CRO networks with scalable 3D models that align with regulatory expectations for safety testing.

Competitive Differentiation 3D spheroid platforms offer robustness, reproducibility, scalability, and high-content readouts, positioning InSphero as a faster, safer alternative to traditional in vitro models; leverage this to win trials requiring organ-specific data in liver, islets, GI, and broader oncology/immunology applications.